Appili Therapeutics Inc. (APLI.TO)
CAD 0.04
(-12.5%)
CAD 0.04
(-12.5%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 827.4 Thousand CAD | 147.6% |
| 2022 | 334.17 Thousand CAD | -75.97% |
| 2021 | 1.39 Million CAD | 0.0% |
| 2020 | - CAD | -100.0% |
| 2019 | 199.1 Thousand CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | - CAD | -100.0% |
| 2023 Q4 | 11.69 Thousand CAD | -97.55% |
| 2023 FY | 827.4 Thousand CAD | 147.6% |
| 2023 Q3 | 478.39 Thousand CAD | 41.83% |
| 2023 Q2 | 337.31 Thousand CAD | 0.0% |
| 2023 Q1 | - CAD | -100.0% |
| 2022 Q1 | - CAD | 0.0% |
| 2022 Q4 | 334.17 Thousand CAD | 0.0% |
| 2022 FY | 334.17 Thousand CAD | -75.97% |
| 2022 Q3 | - CAD | 0.0% |
| 2022 Q2 | - CAD | 0.0% |
| 2021 Q3 | 1.39 Million CAD | 0.0% |
| 2021 FY | 1.39 Million CAD | 0.0% |
| 2021 Q1 | - CAD | 0.0% |
| 2021 Q2 | - CAD | 0.0% |
| 2021 Q4 | - CAD | -100.0% |
| 2020 FY | - CAD | -100.0% |
| 2020 Q1 | - CAD | 0.0% |
| 2020 Q4 | - CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| 2020 Q2 | - CAD | 0.0% |
| 2019 Q3 | 199.1 Thousand CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 FY | 199.1 Thousand CAD | 0.0% |
| 2019 Q4 | - CAD | -100.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Eupraxia Pharmaceuticals Inc. | - CAD | -Infinity% |
| Helix BioPharma Corp. | - CAD | -Infinity% |
| Microbix Biosystems Inc. | 16.51 Million CAD | 94.99% |
| Medicenna Therapeutics Corp. | - CAD | -Infinity% |
| Satellos Bioscience Inc. | - CAD | -Infinity% |
| Oncolytics Biotech Inc. | - CAD | -Infinity% |
| Sernova Corp. | - CAD | -Infinity% |